Enterosys
Private Company
Funding information not available
Overview
Enterosys is a preclinical CRO that has carved out a niche by centering its research on the gut-organ axis, a rapidly growing field in biomedical science. The company offers tailored in vitro and in vivo models to study complex pathologies like metabolic, neurodegenerative, gastrointestinal, and dermatological disorders. By providing gut-centric preclinical data, it aims to help clients de-risk development, accelerate discovery, and enhance the value of their active ingredients. Its CIR accreditation provides clients with tax advantages for R&D collaborations in France.
Technology Platform
Integrated physiology platform utilizing customizable in vitro and in vivo models to study compound effects on specific gut-organ axes (e.g., gut-brain, gut-skin, gut-liver).
Opportunities
Risk Factors
Competitive Landscape
Enterosys competes in the preclinical CRO market, differentiated by its niche focus on gut-organ axes. It faces competition from large, full-service CROs and academic research cores, but its specialized expertise may carve out a defensible position.